To include your compound in the COVID-19 Resource Center, submit it here.

Gleevec: Phase III data; marketed to treat chronic myeloid leukemia (CML)

NVS said an interim analysis of the ongoing 1,106-patient international Phase III IRIS study

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE